Response Genetics, Inc. Announces Pricing of Its Initial Public Offering
LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq:RGDX), today announced the initial public offering of 3,000,000 shares of its common stock at a price of $7.00 per share. Shares of Response Genetics’ stock will begin trading today on the NASDAQ Capital Market under the symbol "RGDX" effective Tuesday, June 5, 2007.
Maxim Group LLC acted as lead underwriter and representative of the underwriters of the offering, and Caris & Company acted as co-manager. Response Genetics has granted the underwriters a 45-day over-allotment option to purchase an additional 450,000 shares of common stock.
The public offering is being made by means of a written prospectus. Copies of the final prospectus relating to the offering may be obtained from: Maxim Group, 405 Lexington Avenue, 2nd Floor, New York, New York 10174, telephone: (800) 724-0761.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws of any such state or jurisdiction.
About Response Genetics, Inc.
Response Genetics, Inc. (“RGI”) (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).
Response Genetics, Inc. Kathleen D. Danenberg President & Chief Executive Officer firstname.lastname@example.org www.responsegenetics.com or
Investor Relations: Strategic Growth International, Inc. Richard E. Cooper - email@example.com Jennifer K. Zimmons, Ph.D. - firstname.lastname@example.org 212-838-1444 www.sgi-ir.com